No Data
Novo Nordisk Says Catalent Buyout to Close Soon as Regulatory Conditions Met
Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More
CFRA Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating, Announces Target Price $122
Unusual Options Activity: YMM, SHAK and Others Attract Market Bets, YMM V/OI Ratio Reaches 100.0
Latest research confirms: Novo-Nordisk A/S Ozempic is associated with a rare risk of vision loss.
① A latest study confirms that Ozempic, a star drug from the Danish pharmaceutical giant Novo-Nordisk A/S, is associated with an increased risk of a rare eye disease that leads to vision loss; ② According to an analysis by Nordic researchers of years of patient records from Denmark and Norway, diabetic patients using Ozempic are more than twice as likely to develop NAION compared to patients using another diabetes medication.
Market Whales and Their Recent Bets on NVO Options
